Teva's $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires
· techtimes.com · popularity 20/100 · 0 similar stories today · Pharmaceuticals & Medical Research (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Samsung Bioepis Teva biosimilar deal announced Monday grants Teva exclusive US rights to two FDA-approved drugs -- RENFLEXIS and ETICOVO -- for up to $420 million, but a federal court's permanent injunction bars ETICOVO from US pharmacies until April 2029, locking the etanercept biosimilar market for Amgen's Enbrel until patent expiry.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.